The Sanofi effort is particularly promising, given the company’s previous experience combating Severe Acute Respiratory Syndrome, a virus that resembles the one causing COVID-19. If clinical trials go well, Sanofi expects to make 600 million doses annually of a COVID-19 vaccine.
However, even if that target were reached in 2021, it would cover less than 10% of the world’s population. And even if a manufacturer such as Sanofi could meet U.S. demand in 2021, it is not obvious that it would or should devote most of its supply to the United States.
Finally, a previous collaboration between Sanofi and the U.S. government offers a cautionary note. Sanofi began working with federal partners on a Zika vaccine in 2016. The partnership collapsed in 2017, though, due to declining disease prevalence and haggling over price.
Join the Conversation
VIP members get the ability to comment on articles.